One example is the bradykinin B2 receptor antagonist deucrictibant, which is being evaluated in two phase II studies (NCT04618211, NCT05047185) for both the treatment of acute attacks and the prophylactic management of HAE.68, 69, 70. Here, BDKRB2 is linked to hereditary angioedema.